Two for one? CAR-T therapy for lymphoma benefits concurrent autoimmune disorders.
作者信息
Bachanova Veronika, Nachman Patrick H
机构信息
Division of Hematology, Oncology, Transplantation, University of Minnesota, Minneapolis, MN, USA.
Division of Nephrology and Hypertension, University of Minnesota, Minneapolis, MN, USA.
出版信息
Bone Marrow Transplant. 2023 Nov;58(11):1175-1176. doi: 10.1038/s41409-023-02084-3. Epub 2023 Aug 19.
Abstract
摘要
相似文献
1
Two for one? CAR-T therapy for lymphoma benefits concurrent autoimmune disorders.一举两得？淋巴瘤的嵌合抗原受体T细胞疗法对并发的自身免疫性疾病有益。
Bone Marrow Transplant. 2023 Nov;58(11):1175-1176. doi: 10.1038/s41409-023-02084-3. Epub 2023 Aug 19.
2
Concurrent remission of lymphoma and Sjögren's disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report.弥漫大 B 细胞淋巴瘤接受抗 CD19 嵌合抗原受体 T 细胞治疗后淋巴瘤和干燥综合征同时缓解：病例报告。
Front Immunol. 2023 Dec 19;14:1298815. doi: 10.3389/fimmu.2023.1298815. eCollection 2023.
3
Preliminary outcomes reported from three randomized controlled trials of CD19 CAR-T cell therapies in large B cell lymphoma.三项关于CD19嵌合抗原受体T细胞（CAR-T）疗法治疗大B细胞淋巴瘤的随机对照试验报告的初步结果。
Mol Ther. 2022 Jan 5;30(1):14-16. doi: 10.1016/j.ymthe.2021.12.007. Epub 2021 Dec 18.
4
Late Events After CD-19 CAR-T Treatment.CD-19嵌合抗原受体T细胞（CAR-T）治疗后的晚期事件
Biol Blood Marrow Transplant. 2020 Jan;26(1):e1-e2. doi: 10.1016/j.bbmt.2019.10.020. Epub 2019 Oct 25.
5
Prognostic value of early imaging following CAR-T cell therapy in diffuse large B-cell lymphoma.嵌合抗原受体T细胞（CAR-T）疗法治疗弥漫性大B细胞淋巴瘤后早期成像的预后价值
Leuk Lymphoma. 2022 Jun;63(6):1492-1495. doi: 10.1080/10428194.2022.2032039. Epub 2022 Feb 3.
6
Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy.CAR T细胞疗法治疗难治性B细胞淋巴瘤的五年疗效
N Engl J Med. 2021 Feb 18;384(7):673-674. doi: 10.1056/NEJMc2030164.
7
Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.第四代抗 CD19 嵌合抗原受体 T 细胞治疗复发/难治性 B 细胞非霍奇金淋巴瘤的 I 期临床试验。
Front Immunol. 2020 Nov 27;11:564099. doi: 10.3389/fimmu.2020.564099. eCollection 2020.
8
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.CD19 和 CD20 靶向嵌合抗原受体 T 细胞联合给药治疗复发/难治性弥漫性大 B 细胞淋巴瘤的 II 期临床试验。
Cancer Med. 2020 Aug;9(16):5827-5838. doi: 10.1002/cam4.3259. Epub 2020 Jul 1.
9
Unresolved questions in the second-line use of CAR-T cells for diffuse large B cell lymphoma.嵌合抗原受体T细胞（CAR-T）用于弥漫性大B细胞淋巴瘤二线治疗中的未解决问题。
Nat Med. 2022 Dec;28(12):2458-2459. doi: 10.1038/s41591-022-02067-9.
10
CAR-T cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis.嵌合抗原受体T细胞（CAR-T）疗法作为大B细胞淋巴瘤二线治疗优于标准治疗：一项系统评价和荟萃分析。
Br J Haematol. 2023 Jan;200(1):e4-e5. doi: 10.1111/bjh.18506. Epub 2022 Oct 25.
引用本文的文献
1
Immune mediated inflammatory diseases: moving from targeted biologic therapy, stem cell therapy to targeted cell therapy.免疫介导的炎症性疾病：从靶向生物疗法、干细胞疗法到靶向细胞疗法。
Front Immunol. 2025 Apr 7;16:1520063. doi: 10.3389/fimmu.2025.1520063. eCollection 2025.
2
Targeted Cellular Treatment of Systemic Lupus Erythematosus.系统性红斑狼疮的靶向细胞治疗
Cells. 2025 Jan 31;14(3):210. doi: 10.3390/cells14030210.
3
Chimeric antigen receptors: "CARs" in the fast lane for rheumatology.嵌合抗原受体：风湿免疫学的“快车道”
Curr Opin Rheumatol. 2024 May 1;36(3):176-183. doi: 10.1097/BOR.0000000000001012. Epub 2024 Mar 26.
4
Chimeric antigen receptor T cell therapy: a new emerging landscape in autoimmune rheumatic diseases.嵌合抗原受体 T 细胞治疗：自身免疫性风湿病领域的新进展。
Rheumatology (Oxford). 2024 May 2;63(5):1206-1216. doi: 10.1093/rheumatology/kead616.
本文引用的文献
1
CD19-targeted chimeric antigen receptor T-cell therapy in patients with concurrent B-cell Non-Hodgkin lymphoma and rheumatic autoimmune diseases: a propensity score matching study.同时患有B细胞非霍奇金淋巴瘤和风湿性自身免疫性疾病患者的CD19靶向嵌合抗原受体T细胞疗法：一项倾向评分匹配研究
Bone Marrow Transplant. 2023 Nov;58(11):1223-1228. doi: 10.1038/s41409-023-02086-1. Epub 2023 Aug 21.
2
Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells.使用靶向CD19的嵌合抗原受体T细胞治疗一名重症系统性硬化症（SSc）患者。
Ann Rheum Dis. 2023 Aug;82(8):1117-1120. doi: 10.1136/ard-2023-223952. Epub 2023 May 5.
3
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.抗 CD19 CAR T 细胞疗法治疗难治性系统性红斑狼疮。
Nat Med. 2022 Oct;28(10):2124-2132. doi: 10.1038/s41591-022-02017-5. Epub 2022 Sep 15.
4
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.西达基奥仑赛治疗复发或难治性大 B 细胞淋巴瘤患者的疗效和安全性（TRANSCEND NHL 001）：一项多中心无缝设计研究。
Lancet. 2020 Sep 19;396(10254):839-852. doi: 10.1016/S0140-6736(20)31366-0. Epub 2020 Sep 1.
5
Anti-CD20-mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives.抗CD20介导的B细胞耗竭在自身免疫性疾病中的应用：成功、失败与未来展望
Kidney Int. 2020 May;97(5):885-893. doi: 10.1016/j.kint.2019.12.025. Epub 2020 Jan 30.
6
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Tisagenlecleucel 治疗成人复发或难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
7
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.阿基仑赛注射液嵌合抗原受体T细胞疗法治疗难治性大B细胞淋巴瘤
N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.
8
Updated assessment of the prevalence, spectrum and case definition of autoimmune disease.自身免疫性疾病的患病率、谱和病例定义的最新评估。
Autoimmun Rev. 2012 Aug;11(10):754-65. doi: 10.1016/j.autrev.2012.02.001. Epub 2012 Feb 23.
9
The risk of lymphoma development in autoimmune diseases: a meta-analysis.自身免疫性疾病中淋巴瘤发生的风险：一项荟萃分析。
Arch Intern Med. 2005 Nov 14;165(20):2337-44. doi: 10.1001/archinte.165.20.2337.
Zotero 插件